Ironwood Pharma (IRWD) Tops Q4 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2016 Investor Update
February 21, 2017 4:01 PM ESTIronwood revenue in 2016 was $274 million, an 83% increase over 2015, driven primarily by 2016 LINZESS® (linaclotide) U.S. net sales of $626 million and expansion of LINZESS commercial margin to 58%
Key pipeline milestones in linaclotide colonic release, vascular/fibrotic diseases, and uncontrolled gout programs
Multiple value-creating catalysts expected in 2017, including 2 commercial launches, 4 mid-stage clinical data readouts and 4 mid- to late-stage trial initiations
R&D Day on Thursday, March 9th to provide detailed discussion of Ironwoods strategy and execution
CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More
